Table 2 Design of the SBRT treatment of HCC models in studies
Variable | Hayeon Kim [17] | Leung [18] | Pollom [19] | Leung [20] |
|---|---|---|---|---|
Cycle period | Every month | Every month | Every month | |
Time horizon | Lifetime | 5 years | Lifetime | 5 years |
Natural history state setting | ||||
Stable disease | No disease progression, stable after treatment | Stable disease | Stable disease after treatment, stable disease after local progression | Stable disease |
Progression of disease | Local recurrence, local or distant metastasis | Disease progression | Local metastasis, distant metastasis | Disease progression |
Death | Death | Death | Death | Death |
Parameter setting and source | ||||
Transition probability | Systemic literature review | Source was one RCT and one sorafenib and SBRT in clinical trial of advanced HCC; the transition probability of the health state was calculated using a formula | Systemic literature review | Source was one stage I/II RCT of SBRT and one stage II RCT |
Life quality | Systemic literature review | Source was one RCT and one sorafenib and SBRT in clinical trial of advanced HCC | Systemic literature review | Source was one stage I/II RCT of SBRT and one stage II RCT |
Cost | Source was one 2014 Medicare payment dataset of the total treatment cost including the potential complication costs, hospitalization, retreatment, and palliative chemotherapy | Source was from 2015 National Health Insurance Research Database of Taiwan, which was mainly the direct medical cost including drug costs, laboratory tests, physician visits, pharmacy dispensing fees, administration and nursing care fees | Source was 2015 Medicare Services physician fee schedule | Source was from 2016 National Health Insurance Research Database of Taiwan, which was mainly the direct medical cost, including drug costs, laboratory tests, physician visits, pharmacy dispensing fees, and treatment costs for grade 3/4 adverse events |
Discount rate | 3% | 3% | 3% | 3% |
Sensitivity analysis | ||||
Method | One-way and probabilistic sensitivity analyses | One-way and probabilistic sensitivity analyses | One-way and probabilistic sensitivity analyses | One-way and probabilistic sensitivity analyses |
Choice of variable | All parameters | All parameters | All parameters | All parameters |
Threshold value (each QALY) | $100,000 | NT $2213,145 | $100,000 | NT $2157,024 |